Allergan

Envy Medical is a biotechnology company specializing in dermatology and medical aesthetics solutions. It develops non-invasive skin rejuvenation therapies aimed at patients with various dermatological conditions. The company utilizes dermal infusion techniques and advanced skincare products containing effective ingredients to address issues such as hyperpigmentation, aging, and acne. By focusing on skin health and appearance, Envy Medical provides its customers with innovative treatments designed to enhance their overall skin quality.

Bonti, Inc. is a biotechnology company based in Newport Beach, California, specializing in the development of neurotoxin products for both aesthetic and therapeutic applications. Founded in 2015 and previously known as Endurance Biotech, Bonti focuses on botulinum neurotoxin serotype E, with its key products including EB-001A for aesthetic use and EB-001T for therapeutic purposes. The company's innovations aim to address unmet medical needs, particularly in treating muscle hyperactivity, which is a significant cause of musculoskeletal pain in various patient populations. Bonti's neurotoxin offers a long-acting, non-opioid local muscle relaxant option, designed to minimize the side effects associated with existing treatments. As of October 2018, Bonti operates as a subsidiary of Allergan plc.

Elastagen is a clinical stage medical company focused on developing products derived from the human protein tropoelastin, which is essential for the elasticity and resilience of various tissues in the body, including skin and blood vessels. The company has created a synthetic version of elastin that mimics the natural protein found in humans. Its advanced product pipeline targets applications in skin rejuvenation, scar remodeling, and tissue repair. With injectable synthetic human elastin and chemically cross-linked tropoelastin for aesthetic uses, Elastagen aims to help patients maintain skin elasticity and suppleness. Founded after acquiring intellectual property rights to elastin technology developed by Professor Weiss at the University of Sydney, Elastagen has successfully secured funding from prominent life science venture capital firms and expanded its operations to include production in Europe and clinical activities in the UK.

Repros Therapeutics Inc. ® was organized on August 20, 1987. We are a development stage biopharmaceutical company focused on the development of new drugs to treat hormonal and reproductive system disorders.

Zeltiq Aesthetics, founded in 2005 and headquartered in Pleasanton, California, is a medical technology company focused on developing non-invasive solutions for the reduction of unwanted fat tissue. The company's flagship product, the CoolSculpting system, employs a patented technology known as Cryolipolysis, which utilizes controlled cooling to selectively target and eliminate fat cells while preserving surrounding skin and tissue. This FDA-cleared treatment provides a non-surgical option for individuals seeking to reduce stubborn fat bulges. Zeltiq distributes its products through a direct sales force and a network of distributors, catering primarily to dermatologists, plastic surgeons, and aesthetic specialists across North America, Europe, the Asia-Pacific, and Latin America. The company was previously known as Juniper Medical, Inc. before rebranding in 2007. As of 2017, Zeltiq operates as a subsidiary of Allergan plc.

LifeCell develops and markets tissue repair products for use in reconstructive, urogynecologic, and orthopedic surgical procedures. Its products include reconstructive and regenerative tissue matrixes, such as Strattice and AlloDerm for plastic, reconstructive, general surgical, burn, and periodontal procedures; Cymetra for injection; Repliform for urogynecologic surgical procedures; GraftJacket for orthopedic surgical procedures; and AlloCraft DBM for bone grafting procedures. Its products are used in applications, such as abdominal wall reconstruction, hernia repair, breast reconstruction, breast plastic surgery, grafting, and ENT/head and neck plastic reconstruction. It offers its products to patients and healthcare professionals through distributors in the United States and internationally. The company was founded in 1986 and is headquartered in Branchburg, New Jersey. As of May 27, 2008, LifeCell Corporation operates as a subsidiary of Kinetic Concepts Inc.

Chase Pharmaceuticals (CPC) is engaged in the identification and clinical development of medically improved, commercially promising, treatments for central nervous system (CNS) disease. The Company was incorporated in 2007 to link emerging technical opportunities in the basic neurosciences to the expanding medical needs of those with neuropsychiatric disease. Operations thus focus on selecting product candidates to license-in, adding value by advancing towards global registration, and licensing-out to commercial partners. There success reflects an exceptional ability to select promising drug candidates, intimate knowledge of the development process as well as our ability to devise the most efficient path to regulatory approval. Since inception, CPC has sought to develop novel compounds that could improve the treatment of AD and related neurodegenerative disorders. Alzheimer’s disease constitutes the largest unmet medical need in neuropsychiatry. No emerging therapies have clearly demonstrated the potential to fulfill this medical need. Symptoms include an increasing loss of memory and other cognitive functions later combined with a variety of neuropsychiatric and behavioral disturbances. Progression is relentless, typically leading to death within 10 to 15 years. AD is now recognized as the third leading killer in the U.S. It is estimated that the 37 million afflicted worldwide cost society over $600 billion annually. As the population ages, this burden will rapidly climb to unsustainable levels. Although US sales of Alzheimer’s disease medications last year topped $4.7 billion, none of the current treatments improve symptoms more than marginally. Moreover, tolerability is poor, dose titration prolonged, and dropout rates high. Chase founders have invented and patented a unique combination of proven, currently marketed pharmaceuticals that we believe will benefit the symptomatic treatment of AD.

Motus Therapeutics is a biotechnology company based in Boston, Massachusetts, focused on developing peptide therapeutics to address unmet medical needs in metabolic diseases, particularly gastrointestinal disorders. The company's lead product candidate, relamorelin, is a ghrelin agonist designed to treat diabetic gastroparesis, a complication associated with diabetes, as well as other gastrointestinal functional disorders. Motus Therapeutics aims to provide innovative solutions for patients suffering from these conditions.

Tobira Therapeutics, Inc. is a biotechnology company focused on the research, development, and commercialization of antiviral compounds aimed at treating serious infectious diseases. Founded in 2006 and based in Princeton, New Jersey, the company specializes in the development of TBR-652 and TBR-220 antagonists, which are designed for the treatment of HIV/AIDS, hepatitis, and other related infectious conditions. Through its innovative approach, Tobira Therapeutics aims to address critical health challenges associated with these diseases.

Akarna Therapeutics is a biopharmaceutical company with offices in San Diego and Cambridge (UK) that is developing novel small molecule therapeutics that target inflammatory and fibrotic diseases. Our lead program is a non-bile acid FXR agonist that is potentially a best-in-class therapeutic for the treatment of nonalcoholic steatohepatitis (NASH), a progressive form of fatty-liver disease for which there are no approved therapies. Akarna’s lead candidate is currently in preclinical, IND-enabling toxicology and safety pharmacology studies with first-in-human studies planned for early 2017.

Vitae Pharmaceuticals is a clinical-stage biotechnology company based in Fort Washington, Pennsylvania, dedicated to discovering and developing novel small molecule drugs for diseases with significant unmet medical needs. Its pipeline includes VTP-43742, currently in Phase I clinical trials for autoimmune disorders such as psoriasis and multiple sclerosis; VTP-38543, in Phase IIa for atopic dermatitis; and BI 1147560, aimed at treating and preventing Alzheimer's disease. Additionally, the company is developing VTP-34072, which is in Phase II trials for type 2 diabetes, and VTP-38443 for acute coronary syndrome. Vitae Pharmaceuticals employs a structure-based drug-design platform, Contour, to create best-in-class compounds targeting large markets that include chronic kidney disease and atherosclerosis. Established in 2001, the company operates as a subsidiary of Allergan plc.

RetroSense Therapeutics is a biotechnology company developing life-enhancing gene therapies designed to restore vision in patients suffering from blindness due to retinitis pigmentosa (RP) and advanced dry age-related macular degeneration (advanced dry-AMD). There are currently no FDA approved drugs to improve or restore vision in patients with these retinal degenerative conditions. The company's approach to using optogenetics in vision restoration is based on pioneering, proprietary research conducted at Wayne State University and Massachusetts General Hospital. Founded in 2009, RetroSense Therapeutics is headquartered in Ann Arbor, Michigan.

ForSight VISION5 was founded in 2010 as the fifth company created by the ophthalmic product incubator, ForSight Labs. ForSight VISION5 is developing non-invasive products that replace eye drops and provide sustained therapy for major eye diseases including glaucoma, dry eye, and allergy. The company is currently in its second Phase 2 clinical study for its lead product, the Helios insert.

Allergan is a $23 billion diversified global pharmaceutical company and a leader in a new industry model - Growth Pharma. The company is anchored by strong and sustainable brand franchises, a leading global generics business, a premier pipeline, highly efficient operations and an experienced management team creating an unrivaled foundation for long-term growth. Driving continued innovation and growth is the combined company’s strong commitment to R&D, with an investment of ~$1.7 billion in 2015, focused on strategic development of innovative and durable value-enhancing products within brands, generics, biologics and OTC portfolios. The Company’s Generics portfolio features more than 1,000 generics, branded generics, established brands and OTC products. The Company is the third largest generic manufacturer in the U.S. and holds a top 5 leadership position in nearly 20 International markets. Allergan has global headquarters in Dublin, Ireland and U.S. Administrative Headquarters in Parsippany, New Jersey, USA.

Anterios Inc. manufactures delivery system based on nanotechnology to administer drugs and cosmetics. Anterios Inc. was formerly known as Encapsion Inc. The company was incorporated in 2006 and is based in New York, New York.

Northwood Medical Innovation

AqueSys, Inc. is an ophthalmic company based in Aliso Viejo, California, specializing in the development and commercialization of innovative implantable devices for glaucoma treatment. Founded in 2005, the company is known for its XEN gel stent, which facilitates the outflow of aqueous fluid from the anterior chamber to the subconjunctival space, effectively lowering intraocular pressure. This device creates a new drainage pathway, enhancing patient outcomes in glaucoma management. AqueSys operates as a subsidiary of Allergan plc, focusing on advancing surgical solutions to improve eye health.

Naurex Inc. is a clinical-stage company based in Evanston, Illinois, focused on developing innovative therapies for depression and other central nervous system disorders. The firm is pioneering a new mechanism for modulating the N-methyl-D-aspartic acid receptor (NMDAR), which distinguishes its approach from existing treatments. Researchers at Naurex have developed a new class of drugs known as glycine-site functional partial agonists (GFPAs), designed to safely modulate the NMDAR. The company's drug development pipeline includes its first-generation molecule, GLYX-13, and a second-generation series, NRX-1050, along with additional compounds derived from its platform of novel NMDAR modulators. Naurex aims to address significant unmet needs in psychiatry and neurology through these advancements.

Oculeve is a start-up MedTech company with a first-in-class connected health technology to address an unmet clinical need in ophthalmology. Early investors included KPCB, NEA, and Versant. In August 2015, Oculeve was acquired by Allergan Plc.

KYTHERA Biopharmaceuticals, Inc., formerly known as AESTHERx, Inc., was founded in August 2005 and is a privately held biopharmaceutical company located north of Los Angeles in southern California. KYTHERA is focused on science and innovation in aesthetic medicine. This market is expanding rapidly driven by an aging population, increasing discretionary income, and an evolution of patient preference toward restorative and preventative care. The company uses the tools of biotechnology to develop prescription therapeutics for this emerging market.

Exemplar is a pharmaceutical company that specializes in developing inhalation products for lungs, nasal passages, and buccal cavities.

MAP Pharmaceuticals, Inc., a development stage company, focuses on developing novel inhalation therapies for respiratory and systemic diseases. It has various proprietary product candidates in clinical development, including Unit Dose Budesonide for pediatric asthma in children from six months to eight years of age and MAP0004 for migraine. The company's product portfolio also includes MAP0005 for the treatment of adolescent and adult asthma, and chronic obstructive pulmonary disease; and MAP0001 for the treatment of Type 1 and Type 2 diabetes via pulmonary delivery using its Tempo inhaler. MAP Pharmaceuticals, Inc. was founded in 2003 and is headquartered in Mountain View, California.

SkinMedica is focused on developing, acquiring, and commercializing products that improve the appearance of skin. SkinMedica markets and sells to physicians, with a focus on aesthetics, both prescription and non-prescription skin care products. The company's full line of aesthetic skin care products includes the revolutionary TNS Essential Serum® and hallmark TNS Recovery Complex®. The formulations in SkinMedica’s clinical skin care collection enhance skin appearance, reduce signs of aging, and provide other skin care benefits. SkinMedica's primary prescription product, VANIQA® (eflornithine hydrochloride) Cream 13.9%, is the only FDA-approved prescription product for the reduction of unwanted facial hair in women. Colorescience Pro’s dermatologist recommended, high-performance cosmetics are formulated to remedy and camouflage specific skin concerns and protect skin from damaging effects of the sun and environment. Colorescience Pro’s luxury aesthetic makeup line is sold in the physician and medical spa channels.

EMKinetics, Inc. provides a therapy to prevent urinary incontinence by using electric pulses. The company is based in San Francisco, California.

Precision Light, Inc. is a medical device company that specializes in the development and distribution of imaging systems designed for aesthetic medical procedures. The company focuses on creating innovative technologies that simulate the outcomes of breast, facial, and body surgeries, particularly in the field of plastic surgery. By providing advanced imaging solutions, Precision Light aims to enhance patient consultations and decision-making processes, allowing individuals to visualize potential results before undergoing procedures.

Vicept Therapeutics, Inc., located in Malvern, Pennsylvania, is a privately held specialty biopharmaceutical company founded in August 2009. The company focuses on developing innovative topically applied therapies aimed at treating erythema, or skin redness, associated with rosacea and other dermatological conditions characterized by redness and flushing. In addition to its research and development efforts, Vicept also manufactures and distributes dermatological therapeutic products, positioning itself as a key player in addressing unmet medical needs in skin health.

Serica Technologies, Inc., a medical device company, develops silk-based biomaterial platforms that are used in tissue repair caused by disease, trauma, or aging. The company offers SeriGel, a long-term bioresorbable silk hydrogel that is used in plastic and reconstructive surgery, and drug delivery; and SeriFascia surgical scaffold implant, which enables the reestablishment of functional collagen sheet-like tissue that has diminished as a result of either surgery or aging. It also provides SeriACL graft, a biocompatible and biodegradable ligament graft that is used for anterior cruciate ligament (ACL) repair; SeriCuff scaffold, which is used in rotator cuff tendon repair; and SeriScaffold surgical mesh that is used to repair and remodel damaged connective tissues. The company's products are used in orthopedics and sports medicine, aesthetic and reconstructive plastic surgery, and multiple additional structural tissue repair applications. Serica Technologies was formerly known as Tissue Regeneration, Inc. and changed its name to Serica Technologies, Inc. in 2006. The company was founded in 1998 and is based in Medford, Massachusetts. As of February 4, 2010, Serica Technologies, Inc. operates as a subsidiary of Allergan Inc.

BAROnova, Inc. is a clinical-stage medical-device company established in 2006 and based in Goleta, California. The company specializes in creating non-surgical, non-pharmacologic devices aimed at inducing weight loss. Its primary product, the TransPyloric Shuttle, is designed to be inserted into the stomach through the mouth via a straightforward endoscopic procedure. This device works by helping patients feel fuller more quickly, maintain that feeling of fullness for a longer duration, and delay gastric emptying. Through these innovative approaches, BAROnova aims to assist individuals in managing their weight effectively.

Esprit Pharma is a pharmaceutical company focused on specialty therapeutics and committed to improving patient well-being in the urology and OB/GYN areas by providing products that contribute to bettering patient outcomes.

EndoArt is a synthetic implant that treats corneal edema by establishing a new form of corneal availability, hence protecting vision and restoring function.

A healthcare products manufacturer focused on marketing breast implants, dermal fillers to correct facial wrinkles.

Oculex Pharmaceuticals is an ophthalmic drug delivery company based in Sunnyvale, California, founded in 1989. The company specializes in the development of therapeutic products aimed at treating sight-threatening diseases, particularly those affecting the back of the eye, such as diabetic macular edema and age-related macular degeneration. Oculex's proprietary technology includes a biodegradable drug delivery system, which allows for the targeted delivery of medications directly within the eye. One of its notable products is Posurdex, an implant designed to release dexamethasone at the site of disease. In November 2003, Oculex Pharmaceuticals was acquired by Allergan, further enhancing its capabilities in the field of ophthalmic treatments.